- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Systemic lupus erythemosus (SLE)
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 1385KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 208KB)
Belimumab – July 2020
Belimumab: Injection 200 mg in 1 mL pre-filled pen; Benlysta®
Last updated
30 October 2020